Saturday, July 18, 2026

 

Study reveals how brain remodeling during adolescence shapes memory



Mouse study sheds new light on how memory circuits mature




Albert Einstein College of Medicine

Jelena Radulovic, M.D., Ph.D. 

image: 

Jelena Radulovic, M.D., Ph.D., Albert Einstein College of Medicine

view more 

Credit: Albert Einstein College of Medicine




BRONX, NY (July 17, 2026) - Scientists have long known that the human brain continues developing well beyond the teenage years, with important changes involving decision-making and emotional regulation extending into the mid-to-late 20s. Now, for the first time, researchers at Albert Einstein College of Medicine have identified a biological process in mice that offers new insight into how memory circuits mature during this extended period of brain development.

Published today in PLOS Biology, the study found that a key memory region of the mouse brain undergoes an unexpected period of remodeling during late adolescence. As those changes unfold, memories formed earlier in life become temporarily more difficult to retrieve before resurfacing later, often with less precise detail. The findings align with growing evidence that adolescence is a dynamic period of brain maturation and identify a biological mechanism that may help explain how access to memories changes during this stage of development.

Using mouse models, the researchers focused on the retrosplenial cortex (RSP), a brain region that plays an important role in organizing and retrieving long-term memories. They discovered that protective mesh-like structures called perineuronal nets, which help stabilize memory circuits, unexpectedly diminished during late adolescence before rebuilding in adulthood. The changes were confined to the RSP and were not observed in the nearby hippocampus, another brain region essential for memory.

"We've known for years that the brain continues developing through adolescence and young adulthood," said senior author Jelena Radulovic, M.D., Ph.D. professor in the Dominick P. Purpura Department of Neuroscience and of psychiatry and behavioral sciences at Einstein.

“Our findings begin to explain what that developmental process looks like in one of the brain's memory circuits and how it can influence the way earlier experiences are recalled.

We do not yet fully understand the consequences of the observed fluctuations of perineuronal nets, but we believe that their reorganization in RSP helps prioritize access to memories formed in adulthood at the expense of those formed in early adolescence. This could help to better adapt to the circumstances and challenges encountered at different life stages.

“Whether remembering early adolescent experiences comes at the cost of adjusting to new ones, is a possibility that we are currently investigating."

Dr. Radulovic is also director of the Psychiatry Research Institute at Montefiore Einstein (PRIME) and holds the Sylvia and Robert S. Olnick Chair in Neuroscience.

The Teenaged Brain Isn't Finished Yet
Previous studies suggested that the memory circuits examined in this study reached maturity during early adolescence. Instead, the researchers found that an important stabilizing system temporarily weakened during late adolescence before recovering in adulthood.

The timing is notable because it corresponds to a period now recognized as one of continued brain maturation in humans. While adolescence was once defined as ending around age 19, neuroscientists increasingly acknowledge that important developmental changes continue well into the 20s. According to the National Institutes of Health, the brain continues developing and maturing into the mid-to-late 20s.

"The behavior matched the biology," said lead author Hui Zhang, Ph.D., a research fellow at Einstein. "The retrosplenial cortex is responsible for older, more established memories. As its stabilizing structures declined, access to memories formed earlier in life became less reliable."

Restoring Memories
To determine how these brain changes affected behavior, the researchers trained mice to associate a specific environment with an unpleasant experience, a mild foot shock. Shortly afterward, the mice remembered the experience and froze when returned to the same chamber. Weeks later, however, many of the mice trained during early adolescence no longer showed that fear response, while mice trained during adulthood retained stable memories over the same period.

When the adolescent mice later experienced another test in a different environment, they once again responded to the original setting, demonstrating that the memories had become temporarily inaccessible rather than erased.

The researchers traced these changes to a decline in key structural proteins that help build and maintain perineuronal nets, along with reduced activity of TGFβ2, a growth factor involved in maintaining those structures. When they reinforced the protective network or restored TGFβ2 activity, the mice regained their ability to retrieve memories formed earlier in life.

By mid-adulthood, many of those memories resurfaced spontaneously, although they had become less precise. Rather than responding only to the original environment, the mice generalized their fear to unfamiliar settings. The researchers note that this pattern resembles the "reminiscence bump," a well-known phenomenon in which adults disproportionately recall memories from adolescence and early adulthood while often remembering the emotional significance of an experience more readily than its specific details. Whether this is due to a random increase of perineuronal nets with advancing age, to their increase in response to similar experiences, or to the replay of past experiences, or some other factors, remains to be established.

The findings may also have implications beyond memory. Schizophrenia and major depression often emerge in humans during late adolescence—the same developmental period in which the researchers observed this extensive remodeling of memory circuits in mice. The authors suggest that, in genetically susceptible individuals, changes in this developmental process could contribute to vulnerability to psychiatric disorders, although additional research will be needed to determine whether similar mechanisms occur in people. 

Additional Einstein authors include Zorica Petrovic, M.S., Elizabeth M. Wood, Ph.D., Ana Cicvaric, Ph.D., Maayan Krispil-Alon, Ph.D., Kendra Parker, B.A., Thomas E. Bassett, Ph.D., Anna Carboncino, Ph.D., and J. Tiago Goncalves, Ph.D. Other authors include Vladimir Jovasevic, Ph.D., Anita L. Guedea, M.S., and Pengfei Yi, Ph.D., at the Feinberg School of Medicine at Northwestern University, as well as Gal Richter-Levin, Ph.D., at the Sagol Department of Neurobiology at the University of Haifa.

The paper, "Retrosplenial Cortical Reorganization During Late Adolescence Introduces Instability of Contextual Memory Circuits" (DOI: 10.1371/journal.pbio.3003908), was supported by NIH grants R01MH108837 and R01MH078064 and the United States-Israel Binational Science Foundation Grant 2019261.

***

About Albert Einstein College of Medicine
Albert Einstein College of Medicine is one of the nation’s premier academic centers for basic science research, clinical investigation, and biomedical education. Located in the Bronx, Einstein is home to nearly 1,000 M.D., Ph.D., and M.D./Ph.D. students and more than 2,000 full-time faculty members. Einstein receives approximately $200M in funding from the National Institutes of Health (NIH) each year and houses six NIH-funded research centers, in cancer, intellectual and developmental disabilities, clinical and translational research, AIDS, and two in diabetes. In partnership with Montefiore Health System, Einstein advances clinical and translational research to accelerate the pace at which new discoveries become the treatments that benefit patients. For more information, please visit einsteinmed.edu, and follow us on  Instagram, LinkedIn, Twitter, Facebook, and view us on YouTube

 

Multisite test strip boosts mosquito-borne virus detection




Maximum Academic Press
Detection system of mbLFIA. 

image: 

Detection system of mbLFIA.

view more 

Credit: Targetome





A research team has developed a multisite bridging-mediated lateral flow immunoassay (mbLFIA) that enables highly sensitive, portable detection of mosquito-borne viruses, using Chikungunya virus (CHIKV) as a model target. By redesigning nucleic acid amplification products to create multiple bridging sites and pairing this strategy with gold@platinum nanoparticle-based colorimetric enhancement, the method achieved a visual detection limit as low as 2 pmol·L−1 for CHIKV. The work offers a promising diagnostic platform for rapid field testing, outbreak surveillance, and infection control, especially in resource-limited regions where conventional laboratory instruments are difficult to access.

Mosquito-borne viruses, including CHIKV, Dengue virus, Zika virus, Yellow fever virus, Japanese encephalitis virus, West Nile virus, and Getah virus, continue to pose growing threats to public health as international travel, trade, and climate-related vector expansion increase transmission risks. Nucleic acid testing provides high accuracy because it detects intrinsic viral gene sequences and can help distinguish viral variants. However, widely used methods such as reverse transcription polymerase chain reaction (RT-PCR), reverse transcription loop-mediated isothermal amplification, rolling circle amplification, and CRISPR-based assays often depend on enzymes, thermal cycling, fluorescence readers, or other specialized equipment. Existing catalytic hairpin assembly-based lateral flow assays have improved portability, but their sensitivity is limited by the small number of sites available for bridging colorimetric probes to the test line. These limitations highlight the need for a simpler, more sensitive, enzyme-free platform suitable for on-site viral detection.

A study (DOI: 10.48130/targetome-0026-0016) published in Targetome on 30 April 2026 by Yanmin Ju's team, China Pharmaceutical University, reports an enzyme-free mbLFIA strategy that strengthens test-strip signals through multisite molecular bridging and Au@Pt nanoparticle-catalyzed color deposition.

The researchers first designed a two-round catalytic hairpin assembly (CHA) system involving four hairpin probes, H1, H2, H3, and H4. When CHIKV target RNA is present, it triggers hybridization between H1 and H2, releasing the target to start additional amplification cycles. The resulting H1H2 complex then activates H3 and H4 to generate H3H4 hybridization products. Unlike conventional products with limited bridging sites, the H3H4 products were engineered with multiple equivalent binding sites, allowing them to connect Au@Pt-DNA probes to the test line through two bridging mechanisms. This design markedly increased the colorimetric signal: at low product concentration, the multisite structure produced a signal 10.8 times and 9.6 times stronger than two limited-site designs. The team then synthesized Au@Pt nanoparticles, confirmed their structure and composition using transmission electron microscopy, X-ray photoelectron spectroscopy, X-ray diffraction, and related analyses, and demonstrated their strong peroxidase-like catalytic activity. These nanoparticles catalyzed the oxidation of 3-amino-9-ethylcarbazole (AEC), forming an insoluble brown-red precipitate on the test line and further amplifying the visual readout. After optimizing reaction temperature, hairpin ratios, reaction time, probe volume, AEC concentration, hydrogen peroxide concentration, and enhancement time, the assay showed a visual detection range from 2 to 10⁴ pmol·L−1 after colorimetric enhancement, compared with 20 to 10⁴ pmol·L−1 for the general assay. Specificity tests showed that the CHIKV signal was significantly stronger than signals from ZIKV, DENV, WNV, YFV, JEV, and GETV. In spiked serum, saliva, and urine matrices, recovery rates remained within 80%–120%, indicating good tolerance to biological samples. Finally, in 36 suspected CHIKV mouse serum samples, mbLFIA identified 16 positives and 20 negatives, matching RT-PCR results with 100% concordance, sensitivity, and specificity.

This study provides a new strategy for strengthening lateral flow assay signals by increasing the number and efficiency of molecular bridging events. By combining enzyme-free CHA amplification, multisite hybridization products, and nanozyme-assisted AEC deposition, the platform improves visual sensitivity without requiring complex instruments. The researchers suggest that mbLFIA could support rapid detection of mosquito-borne viruses in clinics, ports, field stations, and low-resource areas, and may be adapted for broader nucleic acid testing applications in infectious disease surveillance.

###

References

DOI

10.48130/targetome-0026-0016

Original Source URL

https://doi.org/10.48130/targetome-0026-0016

Funding information

This study was financially supported by the National Natural Science Foundation of China (22574173), the Scientific Research Program Project of Drug Regulatory Science, Jiangsu Provincial Medical Products Administration, China (202518), and the Project Program of State Key Laboratory of Natural Medicines (China Pharmaceutical University) (SKLNMZZ2024JS46, SKLNMZZ202510).

About Targetome

Targetome refers to the complete collection of molecular targets (e.g., proteins, RNA or DNA) that interact with and mediate the effect of a specific biomolecule, such as a drug, toxin, metabolites, transcription factor or microRNA, within a biological system. Targetome is an open access journal publishing rigorously peer-reviewed original research articles, reviews, break-through methods, and perspectives that advance our understanding, identification and validation of molecular targets for new drug development.

 

New approaches against fungal infections discovered



A research team from Münster and Athens has used state-of-the-art cryo-electron microscopy to decode the structure of a key fungal transporter




University of Münster




They are the cell’s ‘gatekeepers’: specialised proteins, known as transporters, selectively control which substances enter a cell and which do not. Researchers at the University of Münster and the National and Kapodistrian University of Athens have investigated these transporters in a specific case: the UapA transporter of the model fungus Aspergillus nidulans. The findings are not only relevant to cell biology but could also offer new approaches to treating fungal infections.

These transporters are essential for pathogenic fungal species to bring important nutrients into the cell. Of particular relevance is the fact that homologous transporters are found in humans. These are responsible for the co-transport of vitamin C and sodium ions. Research into the UapA transporter of the model fungus can therefore also provide insights into the structure and function of human transporters. It is also important to note that several Aspergillus species are pathogens capable of causing severe, life-threatening infections in immunocompromised individuals. “Investigating and understanding these transport processes is therefore of particular biomedical significance,” emphasises Prof. Christos Gatsogiannis, who is leading the research at the University of Münster with his team.

The research findings suggest that UapA functions via a specialised ‘elevator-type’ transport mechanism. In this mechanism, the protein consists of a relatively rigid scaffold domain (the ‘shaft’), which is embedded in the membrane, and a mobile transport domain (the ‘elevator’), which binds the substrate. During transport, this ‘elevator’ moves along the scaffold, carrying the substrate from the outside of the cell into the cytoplasm. This process requires precise coordination with membrane lipids and surrounding water molecules. Until now, the molecular basis of this process was poorly understood due to a lack of structural information.

With its new study, the research team has made a significant advance in elucidating this transport mechanism. The research group led by Prof. Christos Gatsogiannis at the Institute of Medical Physics and Biophysics and the Centre for Soft Nanoscience at the University of Münster achieved a decisive breakthrough: using state-of-the-art cryo-electron microscopy, they succeeded in imaging UapA in two different states. The structures were determined at an exceptional resolution of 2.05 Å – one of the highest resolutions ever achieved using a structural determination method for a eukaryotic membrane transporter. This level of detail allows the visualisation of the protein’s architecture, as well as individual water molecules and the surrounding membrane lipids. One of the most striking findings concerns the N-terminal region of the protein: until now, it was assumed that this region had no fixed structure. However, the new data show that the region fulfils a dual function: it helps the transporter to fold correctly and reach the cell surface. It also plays a role in regulating how the transporter functions.

The findings are fully consistent with genetic and functional studies carried out by the research group led by Prof. George Diallinas at the Institute of Biology, National and Kapodistrian University of Athens. They thus expand our understanding of how UapA functions. Transporters such as UapA can be used, amongst other things, for antifungal drugs – that is, medicines used to treat fungal infections – to enable them to enter fungal cells. A deeper understanding of their structure and function could therefore contribute to the development of new therapeutic strategies against fungal infections.

SPAGYRIC HERBALISM

Saffron compound shows promise against fatty liver disease



Maximum Academic Press
Compound screenings identify Crocin II as a potential drug targeting ANGPTL8. 

image: 

Compound screenings identify Crocin II as a potential drug targeting ANGPTL8.

view more 

Credit: Compound screenings identify Crocin II as a potential drug targeting ANGPTL8.





A research team has identified Crocin II, a natural compound derived from saffron, as a promising therapeutic candidate for metabolic dysfunction-associated steatotic liver disease (MASLD). The study shows that Crocin II directly targets angiopoietin-like protein 8 (ANGPTL8), a liver-derived regulator of lipid metabolism and inflammation, and promotes its degradation through the autophagosome–lysosome pathway. By reducing ANGPTL8 protein levels, Crocin II alleviated liver fat accumulation, improved lipid profiles, reduced inflammatory changes, and enhanced glucose and insulin responses in experimental models.

MASLD has become one of the most common chronic liver diseases worldwide, affecting more than one-quarter of adults and closely linked to obesity, dyslipidemia, type 2 diabetes, cardiovascular disease, chronic kidney disease, and liver cancer. Although multiple therapeutic targets have been explored, including pathways involved in bile acid signaling and lipid metabolism, current drug development remains limited by insufficient efficacy, safety concerns, or translational barriers. ANGPTL8 has emerged as a valuable target because it participates in lipid regulation, inflammatory signaling, and hepatic metabolic rhythm. Existing ANGPTL8-targeted approaches, such as antisense oligonucleotides and monoclonal antibodies, have shown potential but face challenges including delivery limitations, high cost, instability, and possible side effects, highlighting the need for small-molecule or natural-compound alternatives.

A study (DOI: 10.48130/targetome-0026-0012) published in Targetome on 03 April 2026 by Chang Liu, Wenxiang Zhang & Siyu Chen's team, China Pharmaceutical University, reports that Crocin II binds ANGPTL8 and reduces MASLD progression by accelerating ANGPTL8 protein degradation.

To identify natural compounds capable of targeting ANGPTL8, the researchers built a saffron-derived small-molecule library containing 70 chemical monomers and performed molecular docking against human and mouse ANGPTL8. Crocin I and Crocin II showed strong predicted binding affinity, with Crocin II emerging as the more powerful candidate. The team then verified this interaction using several complementary assays. Cellular thermal shift assay and drug affinity responsive target stability analysis confirmed that Crocin II interacts with ANGPTL8 and promotes its degradation, while surface plasmon resonance showed that Crocin II had stronger binding affinity than Crocin I. Molecular dynamics simulations further indicated that the Crocin II–ANGPTL8 complex remained structurally stable over time. The researchers next examined how Crocin II reduced ANGPTL8 levels in mouse primary hepatocytes. Crocin II lowered both intracellular and secreted ANGPTL8 in a dose- and time-dependent manner without significant cellular toxicity. Protein stability tests showed that Crocin II shortened the half-life of ANGPTL8, while pathway inhibition experiments demonstrated that this degradation was mainly mediated by the autophagosome–lysosome system. Increased LC3B-II, decreased P62, transmission electron microscopy, and mCherry–eGFP–LC3 fluorescence imaging supported Crocin II-induced autophagic activation. Functional experiments showed that ANGPTL8 promoted lipid accumulation by increasing lipogenic genes such as Fasn, Dgat1, and Cidea and suppressing lipolytic genes such as Atgl. Crocin II reversed these effects and reduced free fatty acid-induced lipid accumulation in hepatocytes. In Angptl8-deficient cells, Crocin II produced little additional lipid-lowering effect, while Angptl8 overexpression weakened Crocin II's protective action, confirming that ANGPTL8 mediates the compound's metabolic benefit. In mice fed a high-fat diet, Crocin II reduced body weight gain, improved glucose tolerance and insulin sensitivity, lowered serum triglycerides, total cholesterol, low-density lipoprotein cholesterol, and the LDL-C/HDL-C ratio, and decreased liver injury markers. Histological staining showed less hepatic lipid deposition and macrophage infiltration, while liver triglyceride and cholesterol levels were markedly reduced. Untargeted lipidomics revealed that Crocin II reshaped hepatic lipid metabolism, reducing many triglyceride, diglyceride, cholesteryl ester, and fatty acyl species. Importantly, no overt toxic effects were observed in the kidney, heart, or spleen.

Together, the study reveals a natural-compound-based mechanism for targeting ANGPTL8 in MASLD. By promoting autophagic degradation of ANGPTL8, Crocin II reduced hepatic steatosis, improved systemic metabolic dysfunction, and showed favorable preliminary safety in animal experiments. The findings support Crocin II as a promising lead compound for future MASLD drug development and reinforce ANGPTL8 as an important therapeutic target for metabolic disease.

###

References

DOI

10.48130/targetome-0026-0012

Original Source URL

https://doi.org/10.48130/targetome-0026-0012

Funding information

This work was financially supported by grants from the National Key R&D Program of China (Grant No. 2022YFA0807200), the National Natural Science Foundation of China (Grant No. 32471201), the Natural Science Foundation of Jiangsu Province (Grant No. BK20220151), the Project of State Key Laboratory of Natural Medicines, China Pharmaceutical University (no. SKLNMZZ2024JS34), the Open Research Fund of Yunnan Characteristic Plant Extraction Laboratory (Grant No. YKKF2024018), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and The National Innovation and Entrepreneurship Training Program for Undergraduates.

About Targetome

Targetome refers to the complete collection of molecular targets (e.g., proteins, RNA or DNA) that interact with and mediate the effect of a specific biomolecule, such as a drug, toxin, metabolites, transcription factor or microRNA, within a biological system. Targetome is an open access journal publishing rigorously peer-reviewed original research articles, reviews, break-through methods, and perspectives that advance our understanding, identification and validation of molecular targets for new drug development.